28326653|t|The impact of childhood maltreatment on the differential efficacy of CBASP versus escitalopram in patients with chronic depression: A secondary analysis
28326653|a|Childhood maltreatment (CM) has been indicated as a predictor of a differential response to antidepressant treatment with psychotherapy compared to medication. In this secondary analysis, we investigated whether the presence of CM results in a differential indication for the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) or escitalopram plus clinical management (ESC). Sixty patients with chronic depression were randomized to either 22 sessions of CBASP or ESC over the course of 8 weeks of acute and 20 weeks of extended treatment at 2 German treatment sites. CM was assessed using the Childhood Trauma Questionnaire and the clinician rated Early Trauma Inventory. Intention-to-treat analyses were used to examine the impact of CM on depression, global functioning, and quality of life. The presence of CM did not result in significant differences in treatment response to CBASP or ESC on any outcome measure after 28 weeks of treatment independent of the type of CM assessment. After 8 weeks, a significant CM Ã— treatment interaction was found for scores on the Montgomery-Asberg Depression Rating Scale. Patients with a history of CM receiving CBASP had a significantly lower response rate compared to patients without CM and to those receiving ESC after 8 weeks. Conclusively, CBASP and ESC are equally effective treatment options for the difficult to treat subgroup of patients with chronic depression and a history of CM. CM may be a predictor of a longer latency of treatment response in the case of psychotherapy. CBASP and escitalopram are equally effective treatment options for chronic depression. Both treatments are also equally effective for the difficult to treat subgroup of patients with chronic depression and a history of childhood maltreatment. Childhood maltreatment may result in a longer latency of treatment response in the case of psychotherapy.
28326653	4	10	impact	T080	C4049986
28326653	14	36	childhood maltreatment	T048	C0008060
28326653	44	56	differential	T080	C0443199
28326653	57	65	efficacy	T080	C1280519
28326653	69	74	CBASP	T061	C0033968
28326653	82	94	escitalopram	T109,T121	C1099456
28326653	98	106	patients	T101	C0030705
28326653	112	130	chronic depression	T048	C0581391
28326653	134	152	secondary analysis	UnknownType	C0683944
28326653	153	175	Childhood maltreatment	T048	C0008060
28326653	177	179	CM	T048	C0008060
28326653	190	199	indicated	T033	C1444656
28326653	205	214	predictor	T078	C2698872
28326653	220	232	differential	T080	C0443199
28326653	233	241	response	T032	C0871261
28326653	245	269	antidepressant treatment	T061	C1096649
28326653	275	288	psychotherapy	T061	C0033968
28326653	289	297	compared	T052	C1707455
28326653	301	311	medication	T121	C0013227
28326653	321	339	secondary analysis	UnknownType	C0683944
28326653	344	356	investigated	T169	C1292732
28326653	369	377	presence	T080	C3854307
28326653	381	383	CM	T048	C0008060
28326653	384	391	results	T169	C1274040
28326653	397	409	differential	T080	C0443199
28326653	410	420	indication	T078	C3146298
28326653	429	482	Cognitive Behavioral Analysis System of Psychotherapy	T061	C0033968
28326653	484	489	CBASP	T061	C0033968
28326653	494	506	escitalopram	T109,T121	C1099456
28326653	512	531	clinical management	T058	C1516615
28326653	533	536	ESC	T109,T121	C1099456
28326653	545	553	patients	T101	C0030705
28326653	559	577	chronic depression	T048	C0581391
28326653	583	593	randomized	T062	C0034656
28326653	607	615	sessions	T077	C1883017
28326653	619	624	CBASP	T061	C0033968
28326653	628	631	ESC	T109,T121	C1099456
28326653	641	647	course	T079	C0750729
28326653	651	658	8 weeks	T079	C0439230
28326653	662	667	acute	T079	C0205178
28326653	672	680	20 weeks	T079	C0439230
28326653	684	692	extended	T169	C0231448
28326653	693	702	treatment	T061	C0087111
28326653	708	714	German	T083	C0017480
28326653	715	730	treatment sites	T082	C0337950
28326653	732	734	CM	T048	C0008060
28326653	739	747	assessed	T052	C1516048
28326653	758	767	Childhood	T079	C0231335
28326653	768	774	Trauma	T080	C1510467
28326653	775	788	Questionnaire	T170	C0034394
28326653	797	806	clinician	T097	C0871685
28326653	807	812	rated	T052	C0871208
28326653	813	835	Early Trauma Inventory	T170	C0282574
28326653	837	864	Intention-to-treat analyses	T062	C2718028
28326653	890	896	impact	T080	C4049986
28326653	900	902	CM	T048	C0008060
28326653	906	916	depression	T048	C0011570
28326653	918	936	global functioning	T060	C0017644
28326653	942	957	quality of life	T078	C0034380
28326653	963	971	presence	T080	C3854307
28326653	975	977	CM	T048	C0008060
28326653	986	992	result	T169	C1274040
28326653	996	1007	significant	T078	C0750502
28326653	1008	1019	differences	T080	C1705242
28326653	1023	1041	treatment response	T201	C0521982
28326653	1045	1050	CBASP	T061	C0033968
28326653	1054	1057	ESC	T109,T121	C1099456
28326653	1065	1080	outcome measure	T081	C0086749
28326653	1087	1095	28 weeks	T079	C0439230
28326653	1099	1108	treatment	T061	C0087111
28326653	1109	1123	independent of	T169	C0332291
28326653	1136	1138	CM	T048	C0008060
28326653	1139	1149	assessment	T058	C0220825
28326653	1157	1164	8 weeks	T079	C0439230
28326653	1168	1179	significant	T078	C0750502
28326653	1180	1182	CM	T048	C0008060
28326653	1185	1194	treatment	T061	C0087111
28326653	1195	1206	interaction	T169	C1704675
28326653	1211	1216	found	T033	C0150312
28326653	1221	1227	scores	T081	C0449820
28326653	1235	1276	Montgomery-Asberg Depression Rating Scale	T170	C4054475
28326653	1278	1286	Patients	T101	C0030705
28326653	1294	1301	history	T033	C0262926
28326653	1305	1307	CM	T048	C0008060
28326653	1308	1317	receiving	T080	C1514756
28326653	1318	1323	CBASP	T061	C0033968
28326653	1330	1349	significantly lower	T081	C4055638
28326653	1350	1363	response rate	T079	C0237629
28326653	1364	1372	compared	T052	C1707455
28326653	1376	1384	patients	T101	C0030705
28326653	1393	1395	CM	T048	C0008060
28326653	1409	1418	receiving	T080	C1514756
28326653	1419	1422	ESC	T109,T121	C1099456
28326653	1429	1436	8 weeks	T079	C0439230
28326653	1438	1450	Conclusively	T080	C2828146
28326653	1452	1457	CBASP	T061	C0033968
28326653	1462	1465	ESC	T109,T121	C1099456
28326653	1478	1487	effective	T080	C1704419
28326653	1488	1497	treatment	T061	C0087111
28326653	1514	1523	difficult	T080	C0332218
28326653	1527	1532	treat	T169	C1522326
28326653	1533	1541	subgroup	T185	C1515021
28326653	1545	1553	patients	T101	C0030705
28326653	1559	1577	chronic depression	T048	C0581391
28326653	1584	1591	history	T033	C0262926
28326653	1595	1597	CM	T048	C0008060
28326653	1599	1601	CM	T048	C0008060
28326653	1611	1620	predictor	T078	C2698872
28326653	1626	1632	longer	T080	C0205166
28326653	1633	1640	latency	T079	C0023103
28326653	1644	1662	treatment response	T201	C0521982
28326653	1670	1674	case	T169	C0868928
28326653	1678	1691	psychotherapy	T061	C0033968
28326653	1693	1698	CBASP	T061	C0033968
28326653	1703	1715	escitalopram	T109,T121	C1099456
28326653	1728	1737	effective	T080	C1704419
28326653	1738	1747	treatment	T061	C0087111
28326653	1760	1778	chronic depression	T048	C0581391
28326653	1785	1795	treatments	T061	C0087111
28326653	1813	1822	effective	T080	C1704419
28326653	1831	1840	difficult	T080	C0332218
28326653	1844	1849	treat	T169	C1522326
28326653	1850	1858	subgroup	T185	C1515021
28326653	1862	1870	patients	T101	C0030705
28326653	1876	1894	chronic depression	T048	C0581391
28326653	1901	1908	history	T033	C0262926
28326653	1912	1934	childhood maltreatment	T048	C0008060
28326653	1936	1958	Childhood maltreatment	T048	C0008060
28326653	1963	1969	result	T169	C1274040
28326653	1975	1981	longer	T080	C0205166
28326653	1982	1989	latency	T079	C0023103
28326653	1993	2011	treatment response	T201	C0521982
28326653	2019	2023	case	T169	C0868928
28326653	2027	2040	psychotherapy	T061	C0033968